GARS1 and non-small cell lung carcinoma: Data from differential proteomics and bioinformatics analyses unraveled that Fraisinib, affecting the catalytic activity of GARS1, can modulate different biological and molecular functions involved in antagonizing the tumoral phenotype of NSCLC A549 cells over time.